Benatar initiated this project to better understand why therapeutic success in the pre-clinical SOD1 mouse model of ALS had failed to translate into meaningful treatments for ALS patients.

He found serious methodological flaws in these animal studies–which are well recognized today, but underappreciated at the time.

Through this review, he identified arimoclomol as one of the few compounds with strong (and relatively rigorous) pre-clinical data, which was the impetus for our phase II trial of arimoclomol in SOD1 ALS.